The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are combination therapies comprising inavolisib, a CDK4/6 inhibitor (e.g., palbociclib, ribociclib or abemaciclib), and letrozole; and methods of treating endocrine-sensitive PIK3CA-mutated, HR+ and HER2– advanced breast cancer in a patient comprising administering a therapeutically effective amount of inavolisib, a CDK4/6 inhibitor (e.g., palbociclib, ribociclib or abemaciclib), and letrozole.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A device for handling biological entities (1) placed in a liquid (2) in a culture vessel (3), comprising a culture vessel mount (4), a main mount (5), a drive unit (6) and a control unit (16), wherein a damping unit (7) is arranged between the culture vessel mount (4) and the main mount (5), wherein the damping unit (7) comprises at least one compliant element (8, 9), wherein the drive unit (6) is configured to move the culture vessel mount (4) relative to the main mount (5), and wherein the control unit (16) is configured to control the drive unit (6) such that the culture vessel mount (4) moves relative to the main mount (5) such that the biological entities (1) are dispersed throughout the liquid (2) in the culture vessel (3). Further, a method for handling biological entities (1) placed in a liquid (2) in a culture vessel (3), preferably by using a device according to any one of claims 1 to 12, wherein at least one culture vessel (3) is placed in a culture vessel mount (4) being arranged on a main mount (5), wherein a damping unit (7) is arranged between the culture vessel mount (4) and the main mount (5), and wherein the culture vessel mount (4) is driven by a drive unit (6) such that a movement is applied to the at least one culture vessel (3) for dispersing the biological entities (1) within the liquid (2).
The present invention relates to compounds of formula (I), wherein R1 to R8, Y, A, Q, X and M are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
The present invention relates to compounds of formula (I), wherein R1 to R8, Y, A, Q, X and M are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides compounds of formula (I); (I) wherein Y, R1, R2, R3, m, and n are as described herein, as well as pharmaceutically acceptable salts thereof. Further, the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
The present invention relates to a method for the generation of single stranded DNA (ssDNA) molecules from circular double stranded DNA (dsDNA) molecules comprising a region of interest.
The present invention relates to liquid and lyophilized pharmaceutical compositions comprising 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3- ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (I), or a pharmaceutically acceptable salt thereof, to processes for their preparation, kits comprising them, and their use in medical treatment.
The present invention provides a flow cytometry method for the detection of target cells in a cerebrospinal fluid (CSF) sample with blood contamination.
G01N 15/12 - Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof T-L-B (I), useful for the modulation of TYK2 protein via degradation, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of autoimmune disorders like type 1 diabetes, ankylosing spondylitis, cutaneous lupus erythematosus, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, systemic sclerosis, psoriasis, Crohn's disease, ulcerative colitis, proteasome-associated autoinflammatory syndromes (PRAAS), ISG15 deficiency, and inflammatory bowel disease; inflammatory disorders like rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis, STING-associated vasculopathy with onset in infancy (SAVI), and inflammatory bowel disease; proliferative disorders like hematological cancer, polycythemia vera, myelofibrosis, essential thrombocythemia, and thrombocytosis; endocrine disorders like polycystic ovary syndrome, Crouzon's syndrome, and type 1 diabetes; neurological disorders like Alzheimer's disease. Aicardi-Goiuteieres syndrome (AGS). Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity' and hypoxia; and/or disorders associated with transplantation like transplant rejection and graft versus host disease.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
Provided herein are combination therapies comprising a BRAF inhibitor (e.g., a compound of formula (I), or a pharmaceutically acceptable salt thereof) and an EGRF inhibitor (EGRFi), as well as pharmaceutical compositions, methods and uses thereof.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to intermediates and processes useful for preparing 1-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide 5 and salts thereof. The present invention further relates to 1-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide and salts thereof when prepared by such processes and to associated pharmaceutical compositions and uses for the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention generally relates to the treatment of inflammatory lung disease, particularly chronic obstructive pulmonary disease (COPD), and to therapeutic agents useful therefor. In particular, the present invention relates to antibodies, including bispecific antibodies, useful for the treatment of inflammatory lung disease. In addition, the invention relates to polynucleotides encoding such antibodies, vectors and host cells comprising such polynucleotides, as well as methods for producing such antibodies.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
17.
PROCESS FOR THE PREPARATION OF A BSMOC-LYS FATTY ACID COMPOUND
The invention relates to a process for the preparation of a Bsmoc Lys fatty acid compound of the formula Ia: Bsmoc-Lys (AEEAc-AEEAc- γ –Glu(O-PROT1)-19-carboxy-nonadecanoyl-O-PROT1)-OH (Ia), wherein AEEAc stands for 2-(2-(2-aminoethoxy)ethoxy)acetic acid and PROT1 is an ester protecting group, and to the use of the compound of the formula Ia for the preparation of peptides.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 333/50 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
C07C 251/02 - Compounds containing nitrogen atoms doubly- bound to a carbon skeleton containing imino groups
C07K 1/06 - General processes for the preparation of peptides using protecting groups or activating agents
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
The invention provides compounds having the general formula (I) or (II) wherein R1, R2, R3, R4, X and Y are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with SARM1.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 491/044 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof T-L-B (I), useful for the modulation of TYK2 protein via degradation, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of autoimmune disorders like type 1 diabetes, ankylosing spondylitis, cutaneous lupus erythematosus, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, systemic sclerosis, psoriasis, Crohn's disease, ulcerative colitis, proteasome-associated autoin fl ammatory syndromes (PRAAS), ISG15 deficiency, and inflammatory bowel disease; inflammatory disorders like rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis, STING-associated vasculopathy with onset in infancy (SAVI), and inflammatory bowel disease; proliferative disorders like hematological cancer, polycythemia vera, myelofibrosis, essential thrombocythemia, and thrombocytosis; endocrine disorders like polycystic ovary syndrome, Crouzon's syndrome, and type 1 diabetes; neurological disorders like Alzheimer's disease. Aicardi-Goiuteieres syndrome (AGS). Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity' and hypoxia; and/or disorders associated with transplantation like transplant rejection and graft versus host disease.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof T-L-B (I), useful for the modulation of TYK2 protein via degradation, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of autoimmune disorders like type 1 diabetes, ankylosing spondylitis, cutaneous lupus erythematosus, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, systemic sclerosis, psoriasis, Crohn's disease, ulcerative colitis, proteasome-associated autoinflammatory syndromes (PRAAS), ISG15 deficiency, and inflammatory bowel disease; inflammatory disorders like rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis, STING-associated vasculopathy with onset in infancy (SAVI). and inflammatory bowel disease; proliferative disorders like hematological cancer, polycythemia vera, myelofibrosis, essential thrombocythemia, and thrombocytosis; endocrine disorders like polycystic ovary' syndrome, Crouzon's syndrome, and type 1 diabetes; neurological disorders like Alzheimer's disease. Aicardi-Goiuteieres syndrome (AGS). Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity and hypoxia: and/or disorders associated with transplantation like transplant rejection and graft versus host disease.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
Herein is reported a novel variant adeno-associated virus (AAV) capsid protein comprising a heterologous peptide or polypeptide covalently inserted in the GH-loop of the capsid protein relative to a corresponding parental AAV capsid protein, wherein the heterologous peptide or polypeptide comprises a recognition sequence of a transglutaminase and the amino acids residues at positions 452-455 or 453-459 of VP1 of AAV-2 (SEQ ID NO: 65) or at the corresponding positions in the capsid protein of another AAV serotype are replaced by the heterologous peptide or polypeptide or inserted at amino acid position 456.
The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I)
The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I)
The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I)
wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07C 33/50 - Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
C07C 205/06 - Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention provides compounds of formula (I): (I) wherein X, Y, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further, the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5, and R6, are as described herein, composition including the compounds and methods of using the compounds.
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5, and R6, are as described herein, composition including the compounds and methods of using the compounds.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
25.
ANTIBODIES THAT SPECIFICALLY BIND MODIFIED OLIGONUCLEOTIDES
The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to a mutant transaminase, a nucleic acid encoding the mutant transaminase, a vector comprising the nucleic acid, a cell comprising the mutant transaminase or nucleic acid and a method for the enzymatic reductive transamination of a ketone and the formation of a primary amine in the presence of mutant transaminase.
Dosing regimens and methods for administering combination therapies combining a CD47 blocking agent and an anti-CD20/anti-CD3 bispecific antibody are provided. The dosing regimens and methods may further include additional therapeutic agents.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention provides compounds having the general formula (I), (II), or (III) wherein R1, R2, R3, R4, R5, X, Y, m, and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with SARM1.
C07D 221/04 - Ortho- or peri-condensed ring systems
C07D 221/16 - Ring systems of three rings containing carbocyclic rings other than six-membered
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/044 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4a, R4b, and R5 are as described herein, composition including the compounds and methods of using the compounds.
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4a, R4b, and R5 are as described herein, composition including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The invention relates to novel compounds having the general formula I
The invention relates to novel compounds having the general formula I
wherein X, R1, R2, R3 and n are as described herein, composition including the compounds and methods of using the compounds.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
32.
METHOD FOR DECELERATING THE DECAY-DISSOCIATION OF C3BBB COMPLEX
The present invention relates to a method for stabilizing the C3bBb complex, a rapidly decaying component of the alternative pathway of the complement system, and stabilized C3bBb complexes and uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
Methods are disclosed for producing a molecule comprising a polypeptide complex formed by interaction between a first polypeptide comprising a CH3 region comprising a knob modification and a second polypeptide comprising a CH3 region comprising a hole modification.
The present invention relates to combination therapies employing an anti-CD20/anti-CD3 bispecific antibody in combination with an anti-CD19/anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides novel compounds having the general formula: (I) wherein R1 to R6, X, Y, and Z are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
The present invention provides novel compounds having the general formula: (I) wherein R1 to R6, X, Y, and Z are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
C07C 323/21 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
Methods of extracting information about protein sequence modifications in a protein are disclosed. Protein data derived from mass spectrometry measurements performed on peptides from at least two enzymatic digests is received. Candidate sequence modifications are identified. A subset of the candidate sequence modifications that have a higher average probability of representing true sequence modifications than the rest of the candidate sequence modifications are determined. The determination of the subset of candidate sequence modifications comprises a step of selecting candidate sequence modifications dependent on the candidate sequence modifications being at amino acid sequence positions that are covered by at least two different peptide species that each contain the modification.
The invention relates to a process for the preparation of a fatty acid compound of the formula (Ia) PROT1-O-20-oxoicosanoyl-L-Glu (AEEAc-AEEAc-OH)-O-PROT1, wherein AEEAc stands for 2-(2-(2-aminoethoxy)ethoxy)acetic acid and PROT1 is an ester protecting group and to the use of the fatty acid compound of the formula (Ia) for the preparation of peptides.
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 237/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.
The present invention generally relates to the treatment of chronic obstructive pulmonary disease (CORD), and to therapeutic agents useful therefor. In particular, the present invention relates to antibodies, including bispecific antibodies inhibiting IL-33 and IL-6, useful for the treatment of inflammatory lung disease. In addition, the invention relates to polynucleotides encoding such antibodies, vectors and host cells comprising such polynucleotides, as well as methods for producing such antibodies.
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention generally relates to antibodies that bind to Tn-MUC-1. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
41.
FLUID CONVEYING ARRANGEMENT, RECIPIENT SYSTEM AND METHOD FOR PROVIDING A FLUID FLOW IN A RECIPIENT SYSTEM
A fluid conveying arrangement (100), preferably for use in a recipient system (200), in particular a cell culture system (200), comprises a main reservoir (1), an impelling unit (2) for establishing a rotational flow (3) of a fluid (4) providable inside said main reservoir (1), at least a first and second auxiliary reservoir (7, 8) and a channel system (9), wherein said channel system (9) fluidly connects said auxiliary reservoirs (7, 8) with an outlet opening (5´) and an inlet opening (5´´) of said main reservoir (1) in a way, that a circulating supply flow (10) of said fluid (4) can be established by said rotational flow (3), wherein said channel system (9) and/or at least one of said reservoirs (1, 7, 8) is adapted for fluidly connecting one or more recipient arrangements (11), preferably one or more cell culture arrangements (11), to be supplied with said fluid (4) by means of said circulating supply flow (10). Furthermore, the invention relates to recipient system (200), preferably a cell culture system (200), and a method for providing a fluid flow in recipient system (200), preferably a cell culture system (200).
The present invention relates to a new process for the preparation of a compound of formula (I) or an acceptable salt thereof (I), at technical scale, as well as novel intermediates thereof.
C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
The present invention generally relates to antibodies that bind to Tn-MUC-1. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
The invention relates to a novel compound having the formula 6-[[(3R)-1-Ethyl-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1,2,4-triazin-5-one or 6-[[(3R)-1-ethyl-3-piperidyl]amino]-3-(2-hydroxy-3-bicyclo[4.2.0]octa-1,3,5-trienyl)-4-methyl-1,2,4-triazin-5-one, and pharmaceutically acceptable salts thereof, compositions including the compound and methods of using the compound.
The invention relates to a novel compound having the formula 6-[[(3R)-1-Ethyl-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1,2,4-triazin-5-one or 6-[[(3R)-1-ethyl-3-piperidyl]amino]-3-(2-hydroxy-3-bicyclo[4.2.0]octa-1,3,5-trienyl)-4-methyl-1,2,4-triazin-5-one, and pharmaceutically acceptable salts thereof, compositions including the compound and methods of using the compound.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
The application relates to pairs of antigen binding molecules, each molecule comprising a target-binding domain, a cytokine receptor-binding domain and an Fc domain, wherein the target-binding domains simultaneously bind the target antigen and the cytokine receptor-binding domains bind subunits of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor-binding domains in presence of the target antigen allows to selectively activate a cytokine receptor and effectively mimic cytokine activity in a targeted manner.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
46.
DECONTAMINATION SYSTEM FOR A MOBILE APPARATUS, ROOM AND METHOD INVOLVING SUCH SYSTEM
A decontamination system (1) configured for decontaminating the ground member (96) of a mobile apparatus (90). In particular, the decontamination system (1) comprising (i) a guiding structure configured for guiding the mobile apparatus (90) through the decontamination system (1), (ii) a cleaning station configured for receiving and cleaning the ground member (96) of the mobile apparatus (90) and (iii) a disinfecting station configured for receiving and disinfecting and/or sterilizing the ground member (96) of the mobile apparatus (90). Such a decontamination system (1) can be used for decontaminating the ground member (96) of a mobile apparatus (90). In particular, it can allow for more efficient and reproducible decontamination of the ground member (96) of the mobile apparatus (90). The invention also relates to a room (20) wherein the said decontamination system (1) is installed and to a method of decontaminating the ground member (96) of a mobile apparatus (90) by means of said decontamination system (1).
Herein is reported a method for separating full AAV particles from empty AAV particles, the method comprising the steps of applying a solution comprising full, empty and partially filled AAV particles to an AAV affinity column comprising an AAV affinity material and thereby binding the AAV particles to the AAV affinity material, wherein the solution has a pH in the range of 7.4 to pH 4,5 eluting full AAV particles from the AAV affinity column by applying a pH gradient from the pH of the solution of the first step to a pH in the range of 4 to 2.5, wherein the pH of the applying step and the pH of the eluting step differ in a least 0.5 pH units, and recovering full AAV particles from the eluate, and thereby separating full AAV particles from empty and partially filled AAV particles.
Herein is reported a method for separating recombinant viral particles from other compounds of a mammalian cell culture broth comprising the steps of adding a silica-based filter aid like diatomaceous earth (DE) or synthetic silica-based filter aid to a mammalian cell culture broth comprising recombinant viral particles at a weight ratio of more than 1:2 DE or synthetic silica-based filter aid /biological wet mass (BWM) to obtain a pre-filtration mixture and subjecting the pre-filtration mixture to alluvial filtration, whereby recombinant viral particles are separated from other compounds of the mammalian cell culture broth.
The present invention describes that a pre-mRNA molecule, which temporarily exists before polyadenylation-site induced cleavage occurs, can be targeted by RNase H recruiting antisense oligonucleotides downstream of a transcripts 3' terminus to reduce expression levels of target genes from which the RNA polymerization originates.
A sample holder (1) for preparing tissue samples (2), preferably 3D model systems, for histological analysis, comprises a base body (3) with at least one recess (4), preferably a plurality of recesses (4), for receiving a tissue sample (2), wherein each of said at least one recess (4) comprises at least one tapered receiving section (5) with a taper (6') extending along a central taper axis (7'), wherein each of said at least one tapered receiving section (5) extends laterally, preferably from the associated recess (4), with regard to an extension direction (4') of the associated recess (4), wherein said central taper axis (7') extends in a plane (8), preferably a common plane (8) for a plurality of tapered receiving sections (5), preferably being at least essentially parallel to a cutting plane (9, 9a, 9b). Furthermore, the invention relates to a mould (16) for a sample holder (1), a method for preparing a sample holder (1) and a method for preparing tissue samples (2).
Herein is reported a mammalian cell comprising a deoxyribonucleic acid encoding a bivalent, bispecific fragment antigen binding (FAB), wherein the deoxyribonucleic acid encoding the bivalent, bispecific fragment antigen binding is stably integrated into the genome of the mammalian cell, wherein the deoxyribonucleic acid encoding the FAB comprises exactly two copies of a first expression cassette und exactly three copies of a second expression cassette and the expression cassettes have in 5' to 3' direction the sequence of first copy of first expression cassette-first copy of second expression cassette-second copy of second expression cassette-second copy of first expression cassette-third copy of second expression cassette, wherein the first expression cassette comprising a nucleic acid encoding the heavy chain of the FAB operably linked to a nucleic acid encoding a first signal peptide, and the second expression cassette comprising a nucleic acid encoding the light chain of the FAB operably linked to a nucleic acid encoding a second signal peptide, wherein the first signal peptide has the amino acid sequence MCHQQLVISWFSLVFLASPAMA (PAMA) (SEQ ID NO: 2), the second signal peptide in the first and third copy of the second expression cassette has the amino acid sequence MGWSCIILFLVATATGVHS (VHS) (SEQ ID NO: 1) and the second signal peptide in the second copy of the second expression cassette has the amino acid sequence MRALLARLLLCVLVVSDSKA (SKA) (SEQ ID NO: 3).
The application relates to immunoconjugates for use in a method of treating bladder cancer in a human patient, wherein the method comprises administering the immunoconjugate to the patient, wherein the immunoconjugate comprises: (i) an antibody that binds to PD-1; and (ii) a mutant IL-2 polypeptide comprising the amino acid substitutions F42A, Y45A and L72G. The immunoconjugates are capable of binding in cis to PD-1 and stimulating IL-2 signalling on the same cell, providing selective IL-2 receptor signalling on PD-1 positive T cells relative to the PD-1 negative T cells. The application also relates to the use of the immunoconjugates in combination with immunotherapeutic agent, which is bacterial strain or an oncolytic virus, such as the BCG vaccine.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides solid forms of (3R)—N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide and solvates thereof, as well as therapeutic uses thereof and pharmaceutical composition comprising them.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
54.
PROCESS FOR THE PREPARATION OF A X-BETA-ALA-GLU(OTBU)-GLY TETRAMER BY LPPS AND ITS USE IN SPPS SYNTHESIS
The invention relates to a process for preparing a tetramer of the formula (I), or salts thereof, wherein R1is hydrogen or is a link to a solid support and PROT is an ester protecting group, to a crystalline polymorph of the tetramer of formula I and its preparation and to its use as intermediate in the preparation of a GLP-1R/GIPR agonist.
C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
The present invention relates to methods for the preparation of an aerosol comprising Fab fragments, compositions for use in said methods and uses thereof.
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/527 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07F 9/6584 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
The present disclosure relates to the fields of molecular biology and nucleic acid technology, and provides polynucleotides encoding molecules of interest. The present disclosure also relates to therapy and prophylaxis of disease.
Embodiments described herein provide methods and systems for predicting a subject response to a therapeutic. The methods and systems generally operate by using a machine learning (ML) component trained using time-series responses and image features to generate time-series responses of a subject to a therapeutic that has been administered to the subject.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06F 18/214 - Generating training patternsBootstrap methods, e.g. bagging or boosting
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
59.
PROCESS FOR THE PREPARATION OF A CHIRAL PYRROLO TRIAZOLE ALCOHOL
The invention relates to a novel process for the preparation of chiral pyrrolo triazole alcohols of the formula I
The invention relates to a novel process for the preparation of chiral pyrrolo triazole alcohols of the formula I
wherein X is a halogen atom, n is an integer of 1, 2 or 3 and wherein the spiral bond “” stands for “” or for “” or mixtures of the enantiomers.
The invention relates to a novel process for the preparation of chiral pyrrolo triazole alcohols of the formula I
wherein X is a halogen atom, n is an integer of 1, 2 or 3 and wherein the spiral bond “” stands for “” or for “” or mixtures of the enantiomers.
The chiral pyrrolo triazole alcohols of the formula I are versatile intermediates for the preparation of compounds that have the potential to serve as active pharmaceutical ingredients in drugs.
B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
60.
THERAPEUTIC USE OF BISPECIFIC ANTI-ABETA/TFR ANTIBODIES
Herein is reported that a bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody can be used for the treatment of a subject that is positive for amyloid plaque deposits in the brain, wherein the treatment comprises the administering of a composition comprising a therapeutically effective amount of the bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody of about 3.6 mg/kg relative to the body weight of the subject about once every four weeks for 2 to 8 times and thereafter continuing the administering with the composition comprising a lower amount of the bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody in the range of about 1.8 mg/kg to 2.4 mg/kg relative to the weight of the subject about once every 12 to 24 weeks.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
61.
THERAPEUTIC USE OF BISPECIFIC ANTI-ABETA/TFR ANTIBODIES
Herein is reported that a bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody can be used for the treatment of a subject that is positive for amyloid plaque deposits in the brain, wherein the treatment comprises the administering of a composition comprising a therapeutically effective amount of the bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody of about 3.6 mg/kg relative to the body weight of the subject about once every four weeks for 2 to 8 times and thereafter continuing the administering with the composition comprising a lower amount of the bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody in the range of about 1.8 mg/kg to 2.4 mg/kg relative to the weight of the subject about once every 12 to 24 weeks.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
62.
SYNTHESIS OF A PEPTIDE INCLUDING STEPWISE SIDECHAIN PREPARATION
The invention relates to the synthesis of a peptide of formula (I) by SPPS, wherein in the final step the side chain is stepwise prepared on the solid phase.
The present invention is concerned with a method for determining the distribution of 14C-labeled AAV particles in different tissues of a mammalian organism. Additionally, this invention describes a radiolabeled AAV particle composition for use in such methods.
A method and system for identifying and localizing lesions and/or features associated with diabetic retinopathy. CF imaging data may be received for a retina of a subject. An image input may be formed for a deep learning model using the CF imaging data. The deep learning model may be used to generate DR lesion detection output based on the image input. The DR lesion detection output may include an output based on segmentation, localization, quantification, and/or some other extraction of information related to the DR lesions and/or features.
Systems and methods for quantifying intraretinal cysts as biomarkers according to cyst turbidity is provided. A set of optical coherence tomography (OCT) volumes for a retina of a subject is received, each OCT volume corresponding to a different timepoint in a set of timepoints, and each OCT volume comprising a set of OCT B-scans. For each OCT volume of the set of OCT volumes, a set of element images is generated that visually identifies ophthalmological elements using ophthalmological element indicators. The ophthalmological element indicators assign a different group of pixels to each ophthalmological element. The ophthalmological elements include a set of intraretinal cysts and a vitreous body. A turbidity score is computed for each intraretinal cyst identified in each OCT volume using the plurality of ophthalmological elements identified by the plurality of ophthalmological element indicators in each OCT volume to thereby form a set of turbidity scores.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
67.
THERAPEUTIC USE OF BISPECIFIC ANTI-ABETA/TFR ANTIBODIES
Herein is reported that a bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody can be used for the treatment of a subject that is positive for amyloid plaque deposits in the brain, wherein the treatment comprises the administering of a composition comprising a therapeutically effective amount of the bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody of about 3.6 mg/kg relative to the body weight of the subject about once every four weeks for 7 times and thereafter continuing the administering with the composition comprising the same amount of the bispecific anti-human amyloid beta peptide/human transferrin receptor 1 antibody about once every three months (Q3M) or about once every six months (Q6M).
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
68.
SPPS SYNTHESIS OF A PEPTIDE COMPRISING A FATTY ACID SIDE CHAIN
The invention relates to the SPPS synthesis of a peptide of formula (I) comprising a fatty acid side chain, wherein in the final synthesis step the fatty acid side chain is coupled to the peptide.
A container closure integrity (CCI) testing method for testing tightness of a stopper closure of a syringe (7), wherein the syringe has a syringe body (71) with a longitudinal axis, a hollow interior extending between an open first axial end and a second axial end with an orifice (712), and an elastic stopper (73) provided through the open first axial end into the hollow interior such that a chamber (74) is formed between the stopper (73) and the second axial end, comprises: providing the syringe (7) in a gas environment comprising a detection gas; moving the stopper (73) inside the hollow interior of the syringe body (71); and sensing for detection gas exiting the chamber (74) of the syringe (7) while moving the stopper (73) inside the hollow interior of the syringe body (71).
G01M 3/22 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for pipes, cables, or tubesInvestigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for pipe joints or sealsInvestigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for valves
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I)
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I)
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I)
wherein R1, R2 and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention provides compounds having the general formula (I), wherein A1, A2, R1, R2, R3, R3', R4, R4', and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
73.
MACHINE LEARNING-ENABLED ANALYSIS OF PROTEIN SEQUENCES AND GENERATION OF PROTEIN SEQUENCES THEREWITH
A method may include determining a protein sequence comprising a plurality of amino acid residues. An embedding computation model may be applied to generate an embedding of the protein sequence. The embedding computation model may have been trained, through contrastive learning, to generate similar embeddings for protein sequences exhibiting a threshold similarity in one or more specific regions and dissimilar embeddings for protein sequences failing to exhibit the threshold similarity in the one or more specific regions. The embedding generated by the embedding computation model may prioritize similarities in the one or more specific regions (e.g., CDR3) over similarities in other regions (e.g., framework region). One or more related groups of protein sequences may be identified based on the embedding of the protein sequence. A visual representation may be generated based on the one or more groups of related protein sequences. Related systems and computer program products are also provided.
The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I) wherein R1, R2, R3a, R3band R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
A computer-implemented method of predicting, simulating, or forecasting values of one or more specified subject-related attributes during a clinical trial comprises: receiving input data comprising: a medical history of a subject, the medical history comprising values of a plurality of subject-related attributes of a subject; and data specifying a requested output, the data comprising: the one or more specified subject-related attributes of the subject and a time frame; and applying a trained generative machine-learning model to the received input data, the trained generative machine-learning model configured to generate output data based on the input data, the output data comprising: respective values of the one or more specified subject-related attributes of the subject in the specified time frame.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I)
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I)
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I)
wherein R1, R2 and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
79.
COMBINATION THERAPY OF A GPRC5D TCB AND CD38 ANTIBODIES
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
80.
COMBINATION THERAPY OF A GPRC5D TCB AND PROTEASOME INHIBITORS
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to systems and methods for analyzing data from motion activity monitoring technology. It is particularly, but not exclusively, concerned with a method for determining motion activity patterns during sleep.
The present invention relates to a process for producing a chiral aromatic amine comprising the steps of
a) providing an aromatic imine, and
b) contacting the aromatic imine from step a) with an imine reductase,
thereby stereoselectively reducing the aromatic imine with the imine reductase to a chiral aromatic amine and to novel imine reductases which are capable to catalyse the reaction.
The present invention provides PD-1-regulated IL-2 immunoconjugates and compositions thereof. The invention also features polynucleotides, vectors, host cells, methods of production, pharmaceutical compositions, methods of treating a disease or disorder, such as cancer, related uses and compositions for use, and kits for use with the one or more methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The invention relates to a compound of formula (I) wherein A1and R1to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The invention relates to a compound of formula (I), wherein A1and A2and R1to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
The invention relates to a compound of formula (I) wherein A1and A2and R1to R7 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The invention relates to a compound of formula (I), wherein R1to R9are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
C07D 239/92 - Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
89.
MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC AND INFLAMMATORY FACTORS
A fusion protein or an antigen-binding fragment or domain thereof comprises a pair of heavy chain and light chain of a VEGF antibody, a pair of heavy chain and light chain of an IL-6 or IL-6R antibody, and a single domain antibody or a binding polypeptide directed against Ang-2 that is linked to each of the VEGF antibody and the IL-6 or IL-6R antibody.
Herein is reported a method for producing recombinant adeno-associated viral particle preparation (rAAVp) comprising the step of cultivating a mammalian cell comprising expression cassettes for a non-adeno-associated viral gene, which is interspaced between two AAV inverted terminal repeats (ITRs), an adeno-associated virus rep gene, an adeno-associated virus cap gene, an adeno-associated virus E1A gene, an adeno-associated virus E1B gene, an adeno-associated virus E2A gene, an adeno-associated virus E4orf6 and an adeno-associated virus VA RNA gene, and thereby producing the rAAVp, wherein the cultivating is at a pH value in the range of and including pH 7.4 to pH 7.6. The yield of the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 is higher than the yield of a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2 and the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 has a higher percentage of full particles than a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2.
A plurality of molecule designs may be generated computationally. One or more property computation models may be applied to determine multiple properties of each molecule design. Each property computation model may be trained to approximate a probability distribution of the possible values of a corresponding property. A cumulative distribution function indicator corresponding to an expected multivariate rank may be determined for each molecule design based on the output of the property computation models. The multivariate rank of a molecule design may quantify the probability that none of its properties can be improved without degrading at least one other property. One or more molecule designs may be selected as candidates for wet lab assessment based on the cumulative distribution function indicator of each molecule design. The molecule designs that are selected for wet lab assessment may exhibit incrementally better properties than those from previous design iterations.
Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for liver damage. In particular, the invention provides methods for patient selection and methods of treatment.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/52 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase involving transaminase
The invention provides an immunoconjugate comprising a mutant FLT3L cytokine and a targeted at least bivalent antibody that binds to CLEC9A, wherein the affinity of the mutant FLT3L is reduced as compared to the wild type FLT3L as measured by surface plasmon resonance (SPR) at 25°Canti and methods of using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The invention provides compounds having the general formula (I) wherein A, L, X, Y, Z, V, W, and R1to R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the5 compounds in the treatment or prevention of diseases that are associated with SARM1.
A61P 25/00 - Drugs for disorders of the nervous system
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
The invention relates to a compound of formula (I) wherein R1to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Provided herein are methods of treating and/or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione ("Compound A, A-S, or A- R"), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.
The invention relates to a tetramer of the formula (I), or salts thereof, wherein R1 is hydrogen or is a link to a solid support and PROT is an ester protecting group or hydrogen, to a process for the preparation of a tetramer of the formula I and to its use as intermediate in the preparation of a GLP-1R/GIPR agonist.
The present invention relates to methods for treating multiple sclerosis (MS) in a patient which in some cases involves subcutaneously administering an anti-CD20 antibody into the patient at a dose of about 920 mg. Compositions, formulations and articles of manufacture with instructions for such use are also included.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
100.
ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
Antisense oligonucleotides for altering the splicing pattern of progranulin, and their use in the treatment of neurological disorders. The antisense oligonucleotides are modified to better increase up-regulation or expression restoration of the Exon1-Exon2 progranulin splice variant in cells.
